Testing orelabrutinib for primary progressive MS
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial tests a daily pill called orelabrutinib to see if it can slow disability progression in people with primary progressive multiple sclerosis (PPMS). It may be an option for patients whose symptoms have been getting worse over the past two years.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old
- You have been diagnosed with primary progressive multiple sclerosis (PPMS)
- Your disability has clearly gotten worse in the last two years
- Your current disability level (EDSS) is between 3.0 and 6.5 (moderate to severe)
- You have not had relapses or been diagnosed with relapsing or secondary progressive MS
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental pill called remibrutinib in people with multiple sclerosis (MS). It uses MRI scans to see how well the drug works at reducing MS activity. This could help people with relapsing or progressive MS.
This trial tests a new treatment called TRX319 for people with progressive multiple sclerosis (MS) that has been getting worse. The study wants to see if this treatment can help slow down disability progression.
This study tests an oral medication called orelabrutinib for people whose multiple sclerosis has changed from relapsing-remitting to secondary progressive. The goal is to see if it can slow down disability worsening that happens even without relapses.
This trial tests whether a pill called orelabrutinib can slow down ALS. It is an early-stage study to check safety and see if it may help people with ALS.
This trial tests an oral medication called remibrutinib to see if it can slow disability progression in people with secondary progressive multiple sclerosis (SPMS). You might join if you have had MS for a while, your symptoms have worsened over the past year, and you haven't had any recent relapses.
This study tests a new oral medication called Rocbrutinib for people with relapsing-remitting multiple sclerosis (RRMS). The drug targets a protein that may help reduce the immune system's attack on the brain and spinal cord. The trial will check if the medication can reduce new brain lesions and slow down disability progression.
Hear when a new Multiple Sclerosis (MS) Primary Progressive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.